Clinical study on the application of HoLEP in prostatic hyperplasia patients with long-term oral anticoagulants

ObjectiveTo analyze the efficacy and safety of transurethral holmium laser enucleation of the prostate (HoLEP) in the treatment of prostatic hyperplasia patients with long-term oral anticoagulants.

MethodsThe clinical data of 205 patients with prostatic hyperplasia were retrospectively analyzed.One hundred patients with oral anticoagulants were set as the observation group, and 105 patients without oral anticoagulants were set as the control group.The operation time, hemoglobin decrease amount, washing time and indwelling catheter time were compared between the two groups.The patients were followed up for 3 months, and the maximum urine flow rate, residual urine volume, international prostate symptom score, and quality of life score after operation were compared between the two groups.

ResultsThe operation in all the patients was successfully completed, and there were no complications such as intraoperative and postoperative blood transfusion, capsule perforation, and electrotomy syndrome.The operation time in the observation group was longer than that in the control group (P < 0.05), and there were no significant differences in the hemoglobin decrease amount, washing time and indwelling catheter time between the two groups after operation (P>0.05).There were no significant differences in the maximum urine flow rate, residual urine volume, international prostate symptom score and quality of life score between the two groups at 3 months after operation(P>0.05).

ConclusionsHoLEP is safe and effective in the treatment of prostatic hyperplasia patients with long-term oral anticoagulants, and is worthy of clinical promotion.